In the Media

Prof. Feng Zhang has been named to STAT’s 2024 STATUS List, which highlights the leaders shaping the future of health and life sciences, reports Dialynn Dwyer for Boston.com. “Among the companies he’s co-founded is Editas Medicine, which as of late 2023 was now the official holder of patent rights to the CRISPR-Cas9 gene editing tool used in the sickle cell therapy Casgevy, and Aera Therapeutics, which in February 2023 raised $193 million in venture funding to develop protein nanoparticles as a way of delivering gene editing,” Dwyer writes.